Evox Therapeutics develops exosome-based therapeutics using its DeliverEX® platform to target and deliver treatments for life-threatening rare diseases with limited existing options. By engineering the natural trafficking capabilities of extracellular vesicles, Evox aims to enhance the efficacy and delivery of therapeutics in challenging medical conditions.
Funding
$165.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
RGFounders
Product
Problem
Many life-threatening rare diseases lack effective treatments due to the difficulty of delivering therapeutic payloads to the specific cells and tissues affected. Traditional drug delivery methods often face challenges in crossing biological barriers, resulting in limited efficacy and potential off-target effects.
Solution
Evox Therapeutics is developing exosome-based therapeutics utilizing its DeliverEX® platform to precisely target and deliver treatments for severe rare diseases. By harnessing the natural trafficking capabilities of exosomes, the company engineers these extracellular vesicles to enhance the delivery and efficacy of therapeutic payloads. This approach aims to overcome the limitations of conventional drug delivery methods, offering a more targeted and effective way to address challenging medical conditions.
Target Audience
The primary target audience includes patients suffering from life-threatening rare diseases and their families, as well as pharmaceutical companies seeking innovative drug delivery solutions.
Features
- DeliverEX® platform for engineering exosomes with enhanced targeting and delivery capabilities
- Exosome engineering to improve therapeutic payload encapsulation and release
- Targeted delivery of therapeutics to specific cells and tissues affected by rare diseases
- Internal and partnered pipeline of exosome-based therapeutics
- Focus on life-threatening rare diseases with limited existing treatment options